Neurogenx 4000PRO Featuring S.E.A.

Technology is Discontinued by the

Patented Holder and Manufacturer

The Synaptic Corporation announces immediate termination of co-branding and distribution

relationship with Neurogenx Innovative Neurogenic Solutions dba Neurogenx NerveCenters.

Denver, CO, June 27, 2017 --(PR.com)-- Today, The Synaptic Corporation announced immediate
termination of its co-branding and distribution relationship with Neurogenx Innovative Neurogenic
Solutions as of June 26, 2017, enabling owners of version Neurogenx 4000PRO featuring S.E.A.
immediate access to the original manufacture service and support through The Synaptic Corporation.

We are proud of the value our technology has created by being the foundation of the Neurogenx
NerveCenter, for the medical providers, their patients and for our shareholders, said Chris Zueger,
President and C.E.O. of The Synaptic Corporation. Taking a very streamlined approach, we began
discussions on a possible continuation of the co-branding of our patented technology with Neurogenx
Innovative Neurogenic Solutions, however, we were unable to reach terms that would have made sense
for the Company and our shareholders. Instead, our focus will be on building strong relationships with the
medical professionals utilizing our patented Neurogenx 4000PRO featuring S.E.A. Technology in their
offices and NerveCenters. We see significant potential for Synaptic Electronic Activation Bio-Medical
Instruments to expand further by offering attractive incentives to co-brand our newest technology. We
feel that as the developer, designer and manufacturer, we create more tangible opportunities for returns
for the medical provider over the moderate to long term. Many Neurogenx 4000Pro Providers have
already benefited from partnering with The Synaptic Corporation. Building a relationship with the
Neurogenx 4000PRO Providers will make available access to our manufacturer service and support and
to the latest Synaptic Electronic Activation Bio-Medical Instruments. The first screen that is seen when
you turn the Neurogenx 4000PRO on reads Welcome to Synaptic Electronic Activation, said Kristin
Zueger, VP of Sales of the Synaptic Corporation, and I would like to personally extend that welcome to
all Neurogenx NerveCenter Providers.

The Synaptic Corporation is focused on customer service driven by Neurogenx 4000PRO customer
feedback and it is The Synaptic Corporation's commitment to deliver the service, support and the latest
product updates that our 4000PRO clientele are accustomed to. The Synaptic Corporation is available
immediately to provide service and support, please visit us at www.synapticcorporation.com.

Founded in 1991, The Synaptic Corporation has proven to be a nationwide leader in Bio-medical
Technology. The company is the designer, developer, and patent holder of Synaptic Electronic Activation
Bio-Medical Instruments including the Synaptic 4000PRO and the Neurogenx 4000PRO featuring S.E.A.
Our Patented Neurogenx 4000PRO featuring S.E.A. technology is the foundation of the Neurogenx
NerveCenters, as well as hundreds of S.E.A. providers across the U.S. The Synaptic Corporation's
mission is to develop, design and patent the latest and most State-of-the-art products and services
designed to provide an effective non-invasive, drug-free way for people to live pain free.

The Synaptic Corporation and 4000PRO are either registered trademarks or trademarks of The Synaptic

Page 1/3
PR.com Press Release Distribution Terms of Use
Corporation in the United States and/or other countries.

The names of actual companies and products mentioned herein may be the trademarks of their respective
owners.

For more information, press only:

Kristin Zueger
800-685-7246
admin@synapticusa.com

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
The Synaptic Corporation
Kristin Zueger
800-685-7246
Contact via Email
www.synapticcorporation.com

Online Version of Press Release:

You can read the online version of this press release at: http://www.pr.com/press-release/721577

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use